J. Thistlethwaite to Lymphocyte Activation
This is a "connection" page, showing publications J. Thistlethwaite has written about Lymphocyte Activation.
Connection Strength
0.230
-
Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol. 1999 Sep 01; 163(5):2358-62.
Score: 0.036
-
Inhibition of T-cell activation by an anti-human class I MHC reactive monoclonal antibody occurs at a point distal to TCR-CD3 mediated signal transduction. Transplant Proc. 1995 Feb; 27(1):395-7.
Score: 0.026
-
Severe combined immunodeficient mice engrafted with human splenocytes have functional human T cells and reject human allografts. J Immunol. 1994 Sep 15; 153(6):2738-49.
Score: 0.025
-
Inhibition of T cell activation by a monoclonal antibody reactive against the alpha 3 domain of human MHC class I molecules. J Immunol. 1994 Aug 01; 153(3):1054-67.
Score: 0.025
-
OKT3 F(ab')2 fragments--retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation. 1991 Aug; 52(2):354-60.
Score: 0.020
-
T-cell activation and lymphokine production induced by antihuman CD3 monoclonal antibodies. Transplant Proc. 1991 Feb; 23(1 Pt 1):81-2.
Score: 0.020
-
T lymphocyte activation following OKT3 treatment. Curr Surg. 1990 Nov-Dec; 47(6):458-9.
Score: 0.019
-
Activation of human T cells in vivo following treatment of transplant recipients with OKT3. Transplantation. 1990 Oct; 50(4):608-12.
Score: 0.019
-
Transplantation and the CD28/CTLA4/B7 pathway. Transplant Proc. 2001 Feb-Mar; 33(1-2):209-11.
Score: 0.010
-
Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation. 1995 Nov 27; 60(10):1171-8.
Score: 0.007
-
A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo. Transplantation. 1994 Jun 15; 57(11):1537-43.
Score: 0.006
-
Effect of a single amino acid mutation on the activating and immunosuppressive properties of a "humanized" OKT3 monoclonal antibody. J Immunol. 1992 Jun 01; 148(11):3461-8.
Score: 0.005
-
Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression. J Immunol. 1992 May 01; 148(9):2756-63.
Score: 0.005
-
Anti-CD3 monoclonal antibody therapy. An approach toward optimization by in vitro analysis of new anti-CD3 antibodies. Transplantation. 1991 Aug; 52(2):361-8.
Score: 0.005